Bay Area Lyme Foundation Announces Grant Application for Two $100,000 Awards for Lyme Disease Research

By Bay Area Lyme Foundation

FOR IMMEDIATE RELEASE

Media Contact:
Tara DiMilia, 908-947-0500, tara.dimilia@TMstrat.com

Bay Area Lyme Foundation Announces Grant Application for Two $100,000 Awards for Lyme Disease Research

‘Emerging Leader Award’ aims to attract new scientific talent to address scientific challenges of Lyme disease

Silicon Valley, California, October 5, 2015—The Bay Area Lyme Foundation, a leading national funder of Lyme disease research in the US, today announced a call for applications for two $100,000 Bay Area Lyme Foundation ‘Emerging Leader Award’ grants.  These awards will be given to two promising scientists who embody the future of leadership in Lyme disease research in the US.  The award recipients will be researchers in academia or the private sector who are currently at the post-doctoral level through the assistant Professor level, or equivalent, who have identified a defined approach to improve diagnostics or therapies for Lyme disease. Important criteria include demonstrated professional and scientific leadership in the biomedical sciences and a strong supporting scientific rationale for the project.  Research efforts funded by the award are required to generate initial proof of concept within 12–18 months.

Investigating and Living with the Elusive Culprit of Lyme Disease

By Bay Area Lyme

Why is it that Lyme disease is so little understood, so hard to diagnose, and so frustratingly difficult to get treated? Such were the questions discussed last night at the first of the new Bay Area Lyme Foundation Speaker Series talks.

Field Mustard by Robert Buelteman
Field Mustard by Robert Buelteman

2014 Emerging Leader AwardJerome Bouquet recipient Jerome Bouquet, PhD, UCSF, began the program with a compelling overview of the history of Lyme disease and its pathology, highlighting some of the complicated attributes of the Lyme-causing spirochete and the manifestations of its infection. He touched on promising new technologies like the Tick Chip and the IBIS-developed Iridica, which use unbiased DNA amplification and multiplex assays with greater sensitivity (and more immediate results) than traditional methods. He also described promising developments in transcriptomics that have illustrated the lingering effects of the disease up to six months after treatment, and